Giles MD - Silence Therapeutics Head VP

SLN Stock  USD 6.60  0.15  2.33%   

Insider

Giles MD is Head VP of Silence Therapeutics PLC
Age 70
Address 72 Hammersmith Road, London, United Kingdom, W14 8TH
Phone44 20 3457 6900
Webhttps://www.silence-therapeutics.com

Silence Therapeutics Management Efficiency

The company has Return on Asset of (0.2154) % which means that on every $100 spent on assets, it lost $0.2154. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6428) %, meaning that it generated no profit with money invested by stockholders. Silence Therapeutics' management efficiency ratios could be used to measure how well Silence Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 14th of December 2024, Return On Tangible Assets is likely to drop to -0.53. In addition to that, Return On Capital Employed is likely to drop to -0.68. At this time, Silence Therapeutics' Fixed Asset Turnover is very stable compared to the past year. As of the 14th of December 2024, Asset Turnover is likely to grow to 0.28, while Non Current Assets Total are likely to drop about 8.2 M.
Silence Therapeutics PLC has 272 K in debt with debt to equity (D/E) ratio of 0.02, which may show that the company is not taking advantage of profits from borrowing. Silence Therapeutics PLC has a current ratio of 3.68, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Silence to invest in growth at high rates of return.

Similar Executives

Showing other executives

INSIDER Age

Troy JDAvidity Biosciences
55
Krishna DVMPrelude Therapeutics
58
MAICD MAICDOpthea
48
FACP MDIGM Biosciences
63
Hoyoung MDCytomX Therapeutics
55
Michael GeromettaOpthea
59
Tia BushCentessa Pharmaceuticals PLC
53
Lauren WhiteC4 Therapeutics
N/A
MBA MDCullinan Oncology LLC
51
Adam HansardApplied Therapeutics
47
Owen WallaceMonte Rosa Therapeutics
55
Saurabh MDCentessa Pharmaceuticals PLC
48
Shoshana ShendelmanApplied Therapeutics
45
Thomas BaetzGenfit
50
Riccardo MDApplied Therapeutics
63
John CastleMonte Rosa Therapeutics
53
Misbah TahirIGM Biosciences
49
Suzette TauberIGM Biosciences
60
Elizabeth MDTarsus Pharmaceuticals
46
Pascal PrigentGenfit
56
Jacquelyn JDCullinan Oncology LLC
46
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid therapeutics in hematology, cardiovascular, and other rare and metabolic indications. Silence Therapeutics plc is headquartered in London, the United Kingdom. Silence Therapeutics is traded on NASDAQ Exchange in the United States. Silence Therapeutics PLC (SLN) is traded on NASDAQ Exchange in USA. It is located in 72 Hammersmith Road, London, United Kingdom, W14 8TH and employs 109 people. Silence Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Silence Therapeutics PLC Leadership Team

Elected by the shareholders, the Silence Therapeutics' board of directors comprises two types of representatives: Silence Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Silence. The board's role is to monitor Silence Therapeutics' management team and ensure that shareholders' interests are well served. Silence Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Silence Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
John Strafford, Alliance Devel
Rhonda Hellums, Chief Officer
Eric Floyd, VP Assurance
Gem Hopkins, Head Communications
Gianine Esposito, Chief Officer
Giles MD, Head VP
Jrgen Wittendorff, VP Manufacturing
Craig MBA, President Officer
Steven MD, Executive Officer
J Gabriel, Chief Officer
MBA MBA, CEO Pres
Marie Lindholm, Chief Officer
Dr JD, Senior Officer
Curtis MD, Chief Officer
MBA MS, Senior Assurance

Silence Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Silence Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Silence Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Silence Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Silence Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Silence Stock

  0.91VALN Valneva SE ADRPairCorr
  0.92ERNA Eterna TherapeuticsPairCorr

Moving against Silence Stock

  0.92DYAI Dyadic InternationalPairCorr
  0.78ESPR Esperion TherapeuticsPairCorr
  0.75BMY Bristol Myers SquibbPairCorr
  0.56GILD Gilead Sciences Sell-off TrendPairCorr
  0.41DNA Ginkgo Bioworks HoldingsPairCorr
The ability to find closely correlated positions to Silence Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Silence Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Silence Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Silence Therapeutics PLC to buy it.
The correlation of Silence Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Silence Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Silence Therapeutics PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Silence Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Silence Therapeutics PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Silence Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Silence Therapeutics Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Silence Therapeutics Plc Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silence Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silence Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.70)
Revenue Per Share
0.429
Quarterly Revenue Growth
(0.93)
Return On Assets
(0.22)
Return On Equity
(0.64)
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.